Edition:
India

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

1.75USD
12:42am IST
Change (% chg)

$0.02 (+1.16%)
Prev Close
$1.73
Open
$1.72
Day's High
$1.75
Day's Low
$1.66
Volume
17,679
Avg. Vol
62,996
52-wk High
$1.98
52-wk Low
$0.92

Chart for

About

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $80.42
Shares Outstanding(Mil.): 71.17
Dividend: --
Yield (%): --

Financials

BRIEF-ArQule Files For Offering Of Up To 17.1 Million Shares

* ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: (http://bit.ly/2ivqMQn) Further company coverage:

07 Dec 2017

BRIEF-Arqule reports dosing in registrational trial of FGFR inhibitor

* Arqule announces dosing in a registrational trial of fgfr inhibitor, derazantinib, for treatment of intrahepatic cholangiocarcinoma

21 Nov 2017

BRIEF-Arqule reports Q3 loss per share $0.09

* Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

09 Nov 2017

BRIEF-ArQule announces $9.5 mln private placement of preferred stock

* ArQule announces $9.5 million private placement of preferred stock

08 Nov 2017

BRIEF-Arqule announces $15.7 mln private placement of common stock

* Arqule announces $15.7 million private placement of common stock

16 Oct 2017

BRIEF-Arqule Inc CEO Paolo Pucci​ buys 19,156 shares of co's common stock on Sept 5

* Arqule Inc CEO Paolo Pucci​ reports purchase of 19,156 shares of co's common stock on Sept 5 at average price of $1.14 per share - SEC filing Source text: (http://bit.ly/2j4eXnk) Further company coverage:

06 Sep 2017

BRIEF-Arqule Q2 loss per share $0.10

* Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

04 Aug 2017

Earnings vs. Estimates